New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 11, 2013
08:06 EDTRNNRexahn receives patent related to tumor cancer treatment
Rexahn Pharmaceuticals announced that it has been issued United States Patent, No. 8,598,173, which covers a method for treating solid cancer tumors including ovarian, breast, prostate, liver, lung, kidney, colon, pancreatic and stomach for its clinical development candidate Supinoxin. Rexahn had previously received a composition of matter patent from the United Stated Patent and Trademark Office covering the structure of Supinoxin. “We are progressing on schedule with our Phase I dose-escalation clinical trial for Supinoxin in cancer patients with solid cancer tumors. Having initiated patient enrollment in August, we expect data in the first half of 2014, which will help inform the study design for future Phase II trials on Supinoxin,” the company said.
News For RNN From The Last 14 Days
Check below for free stories on RNN the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
April 21, 2014
09:01 EDTRNNRexahn presents data from preclinical studies of RX-21101
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use